

## Grifols included in Forbes ranking of ‘America’s Best Employers for Women’

- In 2021, 60% of the company’s staff were women, who made up 75% of all new hires and received two-thirds of all promotions. Goal is to have women in half of all senior management roles by 2030
- Grifols continues to strengthen its diversity and inclusion initiatives across the company to reflect the makeup of the communities in which the company operates
- Earlier this year, Forbes also named Grifols one of ‘America’s Best Large Employers’ as well as one of the ‘75 Best Companies to Work for’ in Spain

**Barcelona, Spain, July 27, 2022** – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced that it has been named one of “America’s Best Employers for Women” in 2022 by Forbes magazine.

In recent years and as part of its sustainability efforts, Grifols has made notable advances in gender equality. At the end of 2021, 60% of the company’s staff were women, who during the year made up 75% of all new hires and received two-thirds of all promotions. What also stands out is the presence of women in roles of greater responsibility, with their number in executive positions rising 13.5% compared with 2020. Grifols wants women in half of all senior management roles by 2030.

One initiative to facilitate career pathways for women in Grifols is The Women’s Leadership Initiative, an employee-established resource group in the U.S. that provides a forum for networking and professional development in which women across the company and all job levels share experiences and insights.

The company’s efforts towards greater gender diversity continue to be recognized. In January 2022 and for the second consecutive year, Grifols was included in the Bloomberg Gender-Equality Index (GEI), which values the practices and policies related to gender equality and diversity of listed companies.

“Forbes selecting Grifols as one of the best places to work for women further validates our work to continue creating a company whose benefits and career-development opportunities attract and retain women as part of an increasingly diverse and inclusive workforce,” said Montse Gaja, Grifols Chief Human Resources Officer, who noted that as part of the company’s broader commitment to women in society it supports a range of women’s sports locally and last year became an official partner of UEFA Women’s Football.

# GRIFOLS

Grifols has continuously enhanced its policies aimed at having a more diverse and inclusive workforce, including but not limited to race, ethnicity, sex, gender, identity, age, disabilities and sexual orientation. The company is committed to a talent pool that reflects the makeup of the communities in which it does business.

At the beginning of this year and reflecting the fact that Grifols has steadily become a top employer of choice, Forbes also named the company one of “America’s Best Large Employers” in 2022 as well as one the “75 Best Companies to Work for” in Spain in 2022.

Grifols, recognized as one of the most sustainable companies in the world, has aligned its own Sustainability Agenda for 2030 with the United Nations plan to achieve the 2030 Sustainability Goals. The company is taking action across areas including gender equality, talent development, social initiatives, the environment, product donations and a more sustainable supply chain, among others.

In 2021, Grifols joined the United Nations Global Compact, the world’s largest corporate sustainability initiative. Since December of that year, Grifols has formed part of the Dow Jones Sustainability World Index (DJSI). In 2020, it entered the DJSI Europe, Euronext Vigeo Europe 120 and the Euronext Vigeo Eurozone 120. Since 2018, it has been in the following stock market sustainability indexes: FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex.

All of the company’s sustainability information is public and available at [Grifols | Sustainability](#).

The Forbes list of [America’s Best Employers for Women](#) features 400 companies and was established through an independent survey by Statista of around 50,000 U.S. employees, including more than 30,000 women, at companies with a minimum of 1,000 employees. Survey participants evaluated companies on a number of criteria, including diversity among top executives and board members, working conditions, wages, parental leave policies, family support, flexibility, representation and pay equity.



---

## MEDIA CONTACT:

**Grifols Press Office**  
[media@grifols.com](mailto:media@grifols.com)  
Tel. +34 93 571 00 02

# GRIFOLS

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 400 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. We provide high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2021, Grifols' economic impact in its core countries of operation was EUR 7.7 billion. The company also generated 141,500 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [grifols.com](https://www.grifols.com)

## LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.